1 / 10

Anticoagulation in Acute Ischemic Stroke

Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator. 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled study. N=624 Dosing: 0.9mg/kg (10% bolus, 90% given over 60 minutes)

Download Presentation

Anticoagulation in Acute Ischemic Stroke

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Anticoagulation in Acute Ischemic Stroke

  2. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled study. N=624 Dosing: 0.9mg/kg (10% bolus, 90% given over 60 minutes) Outcomes: At 12 months tpa patients were 30% more likely to have minimal or no disability. 1996: FDA approved TPA for acute stroke management. Additional Studies: ECASS I/II and Atlantis: Concluded the earlier the better (< 3hrs) and there is improved outcome if no significant infarct on CT.

  3. TPA: Tissue Plasminogen Activator • Inclusion criteria: **Clinical diagnosis of stroke with measurable deficit. ** Time: < 3 hours (based on the last time patient was seen normal) ** Previously independent functional status.

  4. TPA: Tissue Plasminogen Activator • Absolute Exclusion criteria **History: 1. CVA or head trauma 3 months prior 2. Cerebral Aneurysm or known AVM. 3. MI in the 3 months prior 4. Any history of intracranial hemorrhage **Clinical: 1. spontaneously clearing stroke symptoms 2. BP >185 or diastolic >110. **Labs: 1. Platelets <100,000 2. INR >1.7 on oral anticoagulants **Radiology:Evidence of multi-lobar infarction with >33% cerebral involvement or hemorrhage or mass on CT

  5. TPA: Tissue Plasminogen Activator • Relative Exclusion criteria **History: 1. Major surgery <14 days prior 2. GI or GU bleeding <21 days prior 3. LP <7 days prior. 4. Arterial puncture at non-compressible site <7 day prior. **Labs: Glucose <50 or >400

  6. Aspirin Therapy • Aspirin: Only therapy that has been evaluated with RCTs. • Aspirin therapy given within 48 hours of onset of acute ischemic stroke symptoms leads to a significant reduction in the risk of early stroke recurrence/mortality, and leads to improved long-term outcome (IST and CAST). • Recommended dose: Initial 325mg, thereafter 150mg -325mg/day. It may be used in assoc. with DVT prophylaxis. • Contraindications: Receiving TPA, IV heparin, or oral anticoagulants. • Alternatives: clopidogrel, ticlopidine, aggrenox.

  7. IST ( International Stroke Trial) • Design: Unblinded, randomized control trial. • N= 19,435; 467 hospitals in 36 countries. • Treatment arms: 1. no treatment 2. ASA 300mg 3. heparin 5000 units SQ BID 4. Heparin 5000 U SQ BID + ASA 300mg 5. Heparin 12,500 U SQ BID + ASA 300mg 6. Heparin 12, 500U SQ

  8. IST ( International Stroke Trial) • Conclusions regarding ASA therapy : >ASA led to significantly fewer recurrent ischemic stroke. >ASA led to decreased death and dependence at 6 months. >ASA was NOT associated with an excess of hemorrhagic strokes. • Combined analyst of the IST and CAST trial: Of 1000 patients, 9 deaths/recurrent stroke are prevented with ASA therapy in the first few weeks. 13 deaths/recurrent strokes are prevented at 6 months.

  9. Full anticoagulation with IV heparin and LMWH. • Use is not recommended by AHA/ASA and ACCP due to limited evidence of efficacy and increased risk of bleeding complications. • No clinical trial has yet to adequately evaluate full dose-anticoagulation in acute stroke.

  10. Resources: • The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator foracute ischemic stroke. N Engl J Med 1995; 333:1581–1587. • International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997; 349:1569–1581. • ACP medicine Dale and Federman et Al. 2007 2206-2212 • Anti-thrombotic and Thrombolytic Therapy for Ischemic Stroke: Chest 2001;119;300S-320S

More Related